Marion Chevandier

Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results

P. van Damme, I. De Coster, N. Cools, 2021, The Journal of infectious diseases.

OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza

J. Marvel, Y. Leverrier, Fergal Hill, 2021, Frontiers in Immunology.

OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

F. Salguero, T. Courant, F. Boué, 2023, Frontiers in Immunology.